Showing results (391-400 of 417) with videos related to

Sort By:
Pageof 42
Annals of the New York Academy of Sciences|May 14, 2005
In situ hybridization localization of TRH precursor and TRH receptor mRNAs in the brain and pituitary of Xenopus laevisL Galas, I Bidaud, M Bulant, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and racloprideM J Millan, A Newman-Tancredi, M Brocco, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 1, 2023
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry studyMoritz C Neubauer, Guillaume P Nicolas, Andreas Bauman, et al.
Synapse (New York, N.Y.)|December 28, 1999
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive statesM J Millan, A Newman-Tancredi, V Audinot, et al.
The British Journal of Nutrition|February 15, 2001
5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohortA Chango, G Potier De Courcy, F Boisson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2019
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a StudyChristof Rottenburger, Guillaume P Nicolas, Lisa McDougall, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 18, 2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterizationM J Millan, D Cussac, G Milligan, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profileM J Millan, A Gobert, A Newman-Tancredi, et al.
Journal of Neuroendocrinology|November 8, 2025
Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumorsRichard P Baum, Julia G Fricke, Tristan Ruhwedel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 18, 2023
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumoursDamian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
Pageof 42